VirnetX Holding Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are primarily with FY2020. Amounts are in thousands of dollars unless stated otherwise. VirnetX develops and licenses patented internet-security technology and sells related software. Its business model depends substantially on patent licensing, royalties, and litigation outcomes.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $35 | $302,636 |
| Operating expenses | $49,209 | $144,743 |
| Operating income (loss) | $(49,174) | $157,893 |
| Net income (loss) | $(39,593) | $280,429 |
| Basic earnings (loss) per share | $(0.56) | $3.96 |
| Cash from (used in) operations | $(51,722) | $281,389 |
| Cash and cash equivalents, year-end | $142,018 | $192,908 |
| Short-term investments, year-end | $27,254 | $28,348 |
- FY2020 results included a one-time $454,034 Apple payment: $302,428 in royalties, $41,271 in damages, $108,221 in interest, and $2,114 in reimbursed litigation costs. FY2021 had no comparable payment.
- FY2021 SG&A was $52,715, including $41,828 of legal fees. R&D was reported as $5,557 in MD&A, while the statement of operations lists $5,577; the filing text does not provide a clear reconciled value.
- FY2021 included a $9,083 reversal of accrued licensing costs related to litigation. Cash used in financing was $196; no shares were sold under the ATM program in 2021.
- Year-end current assets were $169,492 and current liabilities were $1,021. Cash plus short-term investments totaled $169,272. No debt balance is reported in the provided financial statements.
- Management said available cash and investments should fund current SG&A, including legal expenses, and working capital for the foreseeable future. The company reported no specific revenue or earnings guidance.
Material changes and business developments
- Revenue fell sharply from FY2020 because that year’s results were dominated by the Apple payment; FY2021 revenue was only $35. FY2021 net loss contrasted with FY2020 net income.
- SG&A increased to $52,715 from $45,812, primarily due to higher patent-litigation legal fees. R&D declined from FY2020’s reported $8,830.
- Cash and cash equivalents declined by $50,890 during 2021. Operating cash outflow was $51,722.
- VirnetX reported approximately 205 patents and pending applications. It launched War Room software on March 1, 2022, after year-end, as the first product on its VirnetX One zero-trust security platform.
Outlook, risks, and contingencies
- Apple litigation: A 2020 jury verdict awarded VirnetX $502,800 in the Apple II case. The district court denied Apple’s post-trial motion in January 2021; Apple appealed, and briefing was complete with oral-argument scheduling pending at the filing date. VirnetX cautions that patent challenges or appeal outcomes could reduce, eliminate, or delay any recovery. The company recognizes contingent gains only when realized, so the verdict is not reported as FY2021 revenue or cash.
- Other patent proceedings: Several patent validity disputes and appeals remained pending. Adverse decisions could limit enforcement and licensing value. Litigation is costly and may divert management resources; legal fees were a substantial portion of SG&A.
- Commercial execution: Management sees opportunity in zero-trust security, secure communications, and video conferencing, but acknowledges early-stage product commercialization, limited product revenue, long and unpredictable sales cycles, and dependence on a small customer base and licensing outcomes. No quantified company forecast is provided.
- Other risks: Patent challenges and expirations, privacy and cybersecurity regulation, product defects or security incidents, international expansion, and the effects of COVID-19 could harm results. The company had 24 employees at year-end.
- Related-party item: An arbitration award to McKool Smith of $38,284, including interest, was paid in April 2021; the matter is closed. VirnetX also disclosed aircraft-use payments to an entity controlled by its CEO and chief administrative officer.
Most important facts for investors to verify
- Current status and potential timing or value of the Apple appeal, patent-validity challenges, and any other material litigation; any recovery remains uncertain.
- Whether VirnetX can generate recurring licensing, royalty, and product revenue sufficient to offset its litigation-heavy cost base and operating cash burn.
- Actual customer adoption, sales, and revenue contribution from War Room and the VirnetX One platform after launch.
- Cash and investment levels, future legal spending, and the company’s stated liquidity runway; management’s runway statement is not a guarantee.
- The deferred tax asset’s recoverability: the $19,278 net deferred tax asset depends on estimates of future taxable income and was identified as a critical audit matter.
- The FY2021 R&D disclosure inconsistency ($5,557 in MD&A versus $5,577 in the financial statements) and any subsequent clarification.